A5029749741- Childhood Cancer Survivors' Quality of Life
- Hemophilia Treatment and Research
- Glycosylation and Glycoproteins Research
- Retinoids in leukemia and cellular processes
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Neuroblastoma Research and Treatments
- Chemical Thermodynamics and Molecular Structure
- Neutropenia and Cancer Infections
- Plant Virus Research Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Blood disorders and treatments
- Blood groups and transfusion
- Hemoglobinopathies and Related Disorders
- Monoclonal and Polyclonal Antibodies Research
- Cell Adhesion Molecules Research
- Erythrocyte Function and Pathophysiology
- CAR-T cell therapy research
- Neonatal Health and Biochemistry
- Histone Deacetylase Inhibitors Research
- Herpesvirus Infections and Treatments
- Central Venous Catheters and Hemodialysis
University of Utah
2001-2024
Primary Children's Hospital
1991-2024
Palmetto Hematology Oncology
2000-2014
University of Missouri
2004
Pediatric Oncology Group
2004
Duke University
1990
St. Jude Children's Research Hospital
1986-1988
University of Chicago
1986
National Heart Lung and Blood Institute
1977-1979
National Cancer Institute
1977-1979
Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for aims establish sustained activity, thereby protecting against bleeding without burdensome replacement.
A structurally and functionally related group of genes, lymph node homing receptor (LHR), granule membrane protein 140 (GMP-140), endothelial leukocyte adhesion molecule 1 (ELAM-1) are shown to constitute a gene cluster on mouse human chromosome 1. In situ hybridization mapped GMP-140 bands 21-24 consistent with chromosomal localization LHR. Gene linkage analysis in the indicated that these genes serum coagulation factor V (FV) all map region distal is syntenic 1, no crossovers identified...
Delay-accelerating factor (DAF) protects host cells from complement-mediated damage by regulating the activation of C3 convertases on cell surfaces. Using a panel hamster-human somatic hybrids, DAF gene was mapped to human chromosome 1. In situ hybridization studies using metaphase further localized bands 1q31-41, with largest cluster grains at 1q32. This establishes close linkage genes for four other proteins (C3b/C4b receptor or complement 1, C3d 2, H, and C4-binding protein) that share...
<b><i>Background:</i></b> Many cases of severe neonatal hyperbilirubinemia never have the underlying cause jaundice clearly identified. Thus they are said to ‘idiopathic' jaundice. However, finding exact cause, if it is a genetic condition, can enable informed anticipatory guidance regarding future episodes hemolysis, anemia, or bilirubin cholelithiasis. <b><i>Objective:</i></b> ‘Next generation' gene sequencing often reveal mutations...
Sma 1 / Eco R1 4 PSt -+ " S t s e -PSt FIG. 1. Structure of human PR-3 gene.Exons are indicated by solid boxes, and introns flanking sequence thin lines.Intron phase (0, I, or 11) is shown below each intron.The portions the gene to scale.A partial restriction map shown, sites employed generate subclones used below.
Abstract A reciprocal chromosomal translocation, t(15;17)(q22;q11.2‐12), is characteristic of acute promyelocytic leukemia (APL) French‐American‐British (FAB) subtype M3, and not associated with any other human malignancy. The non‐random pattern the APL translocations suggests that specific genes on chromosomes 15 17 are somehow altered or deregulated as a consequence rearrangement. Translocation breakpoints in patients provide physical landmarks suggest an approach to isolating gene(s)....
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTMolecular analysis of human complement component C5: localization the structural gene to chromosome 9Rick A. Wetsel, Richard S. Lemons, Michelle M. Le Beau, Scott R. Barnum, Deborah Noack, and Brian F. TackCite this: Biochemistry 1988, 27, 5, 1474–1482Publication Date (Print):March 8, 1988Publication History Published online1 May 2002Published inissue 8 March...
Abstract This retrospective study examined the longitudinal hospital outcomes (costs adjusted for inflation, days, and admissions) associated with treatment of pediatric, adolescent, young adult acute lymphoblastic leukemia ( ALL ). Patients between one 26 years age newly diagnosed , who were treated at Primary Children's Hospital PCH ) in Salt Lake City, Utah included. Treatment hospitalization data retrieved from system‐wide cancer registry enterprise warehouse. is a member Oncology Group...
Abstract Introduction Recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) has been shown to be an effective, well-tolerated treatment for patients severe hemophilia B who had previously received replacement therapy. This study investigated the safety and efficacy of rIX-FP in untreated (PUPs). Methods Patients moderately severe/severe (≤2% FIX) FIX products (25–75 IU/kg) prophylaxis weekly or on-demand over ≥50 exposure days (EDs). Primary outcomes were...
Acute promyelocytic leukemia (subtype M3) is characterized by malignant promyelocytes exhibiting an abundance of abnormally large or aberrant primary granules. Myeloperoxidase (MPO) activity these azurophilic granules, as assessed cytochemical staining, unusually intense. In addition, M3 universally associated with a chromosomal translocation, t(15;17)(q22;q11.2). this report, the MPO gene was localized to human chromosome 17 (q12-q21), region breakpoint on in t(15;17), somatic cell hybrid...
Abstract Polymorphisms of glutathione S-transferase (GST) enzymes have been correlated with altered risk several cancers, as well response and toxicity from cancer chemotherapy. We report a low cost, highly reproducible specific PCR-based high-throughput assay for genotyping different GSTs designed use in large clinical trials. In comparison to an alternative method (single nucleotide extension), the sensitivity specificity high throughput was shown be 92 97%, respectively, depending on...
DNA from a tertiary mouse cell transformant containing amplified human sequences encoding myeloid membrane glycoprotein, gp150, was used to construct bacteriophage lambda library. A single recombinant phage 12 kilobases (kb) of isolated, and molecular subclones were then isolate the complete gp150 gene placental genomic The intact gene, assembled three phages, proved be biologically active when transfected into NIH 3T3 cells. Molecular probes locus annealed with 4.0-kb polyadenylated RNA...
Objectives Recombinant tissue plasminogen activator, alteplase, began to be commonly used restore the patency of occluded central venous catheters (CVCs) as urokinase production was halted in late 1990s. However, alteplase often requires an extended dwell time CVCs. In adults, reteplase, a newer thrombolytic agent, has been reported CVCs 30 minutes. The authors prospectively evaluated safety and efficacy reteplase restoring children with cancer. Methods This dose escalation trial. initiated...